0000950170-22-015519.txt : 20220808 0000950170-22-015519.hdr.sgml : 20220808 20220808160759 ACCESSION NUMBER: 0000950170-22-015519 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220802 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220808 DATE AS OF CHANGE: 20220808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 221144400 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-278-8930 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 atra-20220802.htm 8-K 8-K
0001604464false00016044642022-08-022022-08-02

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 02, 2022

 

 

Atara Biotherapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36548

46-0920988

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

611 Gateway Boulevard

Suite 900

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 278-8930

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

ATRA

 

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 1.01 Entry into a Material Definitive Agreement

As previously disclosed, on May 13, 2022, Atara Biotherapeutics, Inc. (the “Company”) received written notice of termination from Bayer AG (“Bayer”) of the Research, Development and License Agreement dated December 4, 2020 by and between the Company and Bayer (the “License Agreement”), pursuant to which the Company granted Bayer an exclusive, field-limited license under the applicable patents and know-how owned or controlled by the Company and its affiliates covering or related to ATA2271 and ATA3271. On August 2, 2022, the Company and Bayer entered into a Termination, Amendment and Program Transfer Agreement (the “Termination Agreement”). The Termination Agreement terminates the License Agreement and each of the Manufacturing and Supply Agreement, the Pharmacovigilance Agreement, the Quality Agreement and the Technology Transfer Agreement, entered into between the Company and Bayer in March 2022, effective as of July 31, 2022.

Under the terms of the Termination Agreement, Bayer will pay the Company $4.2 million in cash for certain contractual activities performed by the Company until effectiveness of the termination and return all rights and licenses granted by the Company to Bayer under the License Agreement to the Company, with the exception of an internal research license to certain know-how granted under the License Agreement. The Company has full rights to continue the clinical development and future commercialization of the programs worldwide.

The foregoing summary of the Termination Agreement does not purport to be complete and is qualified in its entirety by reference to the Termination Agreement, a redacted version of which will be filed with the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2022.

On August 2, 2022, the Company and Charles River Laboratories entered into an Amendment No. 3 to the Commercial Manufacturing Agreement (the “Amendment”). The Amendment, among other things, extended the term of the Commercial Manufacturing Agreement through January 31, 2023, effective as of July 1, 2022.

The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a redacted version of which will be filed with the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2022.

Item 2.02 Results of Operations and Financial Condition.

On August 8, 2022, the Company announced certain financial results for the second quarter ended June 30, 2022. A copy of the Company’s press release, titled “Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update” is furnished as Exhibit 99.1 hereto.

The information (including Exhibit 99.1) is being furnished in this Item 2.02 “Results of Operations and Financial Condition” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.

Item 2.05 Costs Associated with Exit or Disposal Activities

On August 8, 2022, the Company announced a reduction in its workforce plan that will impact approximately 20% of its current employees. The Company expects to substantially complete the workforce reduction by October 7, 2022.

The Company expects to recognize approximately $6.0 million in total for severance and related benefits for employees laid off under the reduction in workforce plan. These charges are primarily one-time termination benefits and are all cash charges. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction.

Additional details will be provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

In connection with the reduction in workforce, the employment of Kristin Yarema, the Company’s Senior Vice President and Chief Commercial Officer, will terminate effective as of November 15, 2022. Pursuant to the terms of the Executive Employment Agreement dated as of January 2, 2020 between Dr. Yarema and the Company, Dr. Yarema will be entitled to receive severance benefits of 12 months of base salary continuation and, subject to her timely election of coverage, payment by the Company of up to 12 months of continued health care benefits.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

 

Description

 

 

99.1

 

Press Release, dated August 8, 2022

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

Forward-Looking Statements

This Current Report on Form 8-K contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities, or future events or conditions, including plans related to the reduction in the Company’s workforce. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the ongoing COVID-19 pandemic and the war in Ukraine, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of the Company’s cash resources and need for additional capital; and other risks and uncertainties affecting the Company’s and its development programs, including those discussed in the Company’s filings with the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

ATARA BIOTHERAPEUTICS, INC.

 

 

 

 

Date:

August 8, 2022

By:

/s/ Utpal Koppikar

 

 

 

Utpal Koppikar
Chief Financial Officer

 

 EX-99.1 2 atra-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update

 

Atara to Focus on R&D Activities Prioritizing Upcoming Milestones for Key Pipeline Assets

 

ATA188 Phase 2 EMBOLD Study Interim Analysis Completed with Target Enrollment Achieved; Primary Endpoint Data Read Out Planned for October 2023

 

FDA Recommended Pathway to Potential Tab-cel BLA Filing Without Need for New Clinical Trial; European Commission Approval on Track for Q4 2022

 

ATA3219 on Track for Q4 2022 IND Submission

 

Conference Call and Webcast Today at 1:30 p.m. PDT / 4:30 p.m. EDT

 

 

SOUTH SAN FRANCISCO, Calif.--August 8, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2022, an update to its corporate strategy, recent business highlights, and key upcoming catalysts.

 

“We are excited about the transformative potential of ATA188 in MS and are pleased that as a result of our significant and constructive engagement, the FDA has recommended a possible path towards a tab-cel BLA filing without the need for a new clinical study,” said Pascal Touchon, President and Chief Executive Officer of Atara. “Atara’s R&D-centered strategy, clear portfolio prioritization, and purposeful partnerships are positioning us for success in reaching critical value-generating milestones for our key pipeline assets. I would like to extend my sincere gratitude and thanks to Atara’s staff for their significant contributions and unwavering commitment to advancing truly innovative medicines for patients in need."

 

Corporate Strategy Update

•
Atara announced plans to focus its activities as a leaner organization centered on R&D to further advance the Company’s innovative pipeline, while reducing cash burn
o
Staff will be reduced by approximately 20% across the organization
o
Future annual cash burn is anticipated to be reduced by over 20%, extending Atara’s cash runway into Q1 2024
•
Leveraging its differentiated allogeneic T-cell therapy platform and unique clinical experience in over 500 patients treated, Atara will prioritize R&D activities over the next 18 months on three core priorities:
o
Clinical development of ATA188, our potentially transformative Phase 2 asset for progressive multiple sclerosis
o
EU and potential U.S. regulatory filings and approvals for tab-cel while seeking a commercial partner for tab-cel in the U.S., including all related activities and costs, which is expected to further extend the Company’s cash runway
o
Anticipated Q4 2022 IND filing for ATA3219, a potential best-in-class allogeneic CD19 CAR T, with the potential to address the significant opportunity in the field for improving durable clinical response in hard-to-treat B-cell malignancies
•
These actions are part of a broader ongoing strategy to focus the organization on R&D, building on the previously announced manufacturing and commercialization collaborations with FUJIFILM Diosynth Biotechnologies (FDB) and Pierre Fabre, respectively, and continuing with the R&D-focused prioritization announced today

 

 

 

ATA188 for Progressive Multiple Sclerosis (MS)

•
Atara completed the Phase 2 EMBOLD study Interim Analysis (IA) in patients with progressive MS in June 2022 and the Company determined no sample size adjustment or modification would be made to the study
•
Based on enrollment at the end of July, approximately 90 patients are planned to be included in the read out of the study primary endpoint of confirmed disability improvement by EDSS at 12 months. Communication of these data is planned to occur at an appropriate forum in October 2023
•
Atara continues to plan for Phase 3 readiness, including interacting with the U.S. Food & Drug Administration (FDA) based on two Fast Track designations, and further developing its proprietary large-scale bioreactor manufacturing process
•
New Phase 1 MRI data providing further evidence of the potential clinical impact of ATA188 in progressive MS patients, as well as updated OLE data, are planned for presentation at an appropriate forum in Q4 2022

 

Tabelecleucel (tab-cel®) for Post-Transplant Lymphoproliferative Disease (PTLD)

•
Based on constructive discussions with Atara, the FDA recommended a possible path to a Biologics License Application (BLA) submission that does not require a new clinical trial
•
Following planned interactions with FDA, Atara intends to provide further guidance on progress to a BLA submission at our next quarterly call
•
The European Medicines Agency (EMA) review of tab-cel is on-track and Atara anticipates European Commission (EC) approval in Q4 2022
o
Atara has successfully completed all six pre-approval inspections required to support the Marketing Authorization Application (MAA) for tab-cel in Europe

 

CAR T Programs

 

ATA2271/ATA3271 (Solid Tumors Over-Expressing Mesothelin)

•
Following Bayer’s strategic review and asset-level prioritization of its pipeline, the exclusive worldwide licensing agreement for next-generation mesothelin-directed CAR T-cell therapies ATA2271, an autologous version, and ATA3271, an armored allogeneic T-cell immunotherapy has been terminated
•
Accordingly, the IND for ATA3271 is paused pending funding for clinical development
•
Following the findings of the Memorial Sloan Kettering (MSK)-generated autopsy report and correlative data analyses, Atara intends to continue supporting the clinical development of ATA2271 through our collaboration with MSK and a protocol amendment to be discussed shortly with the FDA

 

ATA3219 (B-cell Malignancies)

•
Atara continues to make progress toward the anticipated IND filing for ATA3219 in Q4 2022. This allogeneic EBV CD19 CAR T program, using an optimized manufacturing process, is enriched for a memory T-cell phenotype and continues to show robust activity in preclinical studies

 

Second Quarter 2022 Financial Results

•
Cash, cash equivalents and short-term investments as of June 30, 2022 totaled $331.3 million, as compared to $301.8 million as of March 31, 2022. The increase includes the impact of net proceeds of $94.8 million from the sale of the ATOM facility during the second quarter

 

 

•
Atara believes that its cash and investments as of June 30, 2022, together with the expected reductions in operating cash burn, will be sufficient to fund the Company’s planned operations into the first quarter of 2024
•
Net cash used in operating activities was $64.0 million for the second quarter 2022, as compared to $61.6 million for the same period in 2021
•
Atara reported net income of $18.5 million, or $0.18 per share, for the second quarter 2022, as compared to a net loss of $83.8 million, or $0.91 per share, for the same period in 2021. Second quarter 2022 net income included a gain on the sale of the ATOM facility of $50.2 million.
•
License and collaboration revenue was $51.6 million for the second quarter 2022, primarily consisting of deferred revenue recognized due to the termination of the Bayer Collaboration Agreements, as compared to $3.9 million for the same period in 2021. We anticipate that license and collaboration revenues will decrease substantially in future quarters due to the termination of the Bayer Agreements.
•
Total operating expenses include non-cash expenses of $15.6 million for the second quarter 2022, as compared to $16.1 million for the same period in 2021
•
Research and development expenses were $64.9 million for the second quarter 2022, as compared to $68.5 million for the same period in 2021
o
The decrease in the second quarter 2022 was primarily due to lower employee-related and overhead costs as a result of the FDB transaction, partially offset by increased spending on the Company’s ATA188 and CAR T programs
o
Research and development expenses include $7.9 million of non-cash stock-based compensation expenses for the second quarter 2022 as compared to $8.3 million for the same period in 2021
•
General and administrative expenses were $18.8 million for the second quarter 2022, as compared to $19.4 million for the same period in 2021
o
General and administrative expenses include $6.2 million of non-cash stock-based compensation expenses for the second quarter 2022, as compared to $5.5 million for the same period in 2021

 

Conference Call and Webcast Details

Atara will host a live conference call and webcast today, Monday, August 8, 2022, at 4:30 p.m. EDT to discuss the Company’s financial results and recent operational highlights. Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID 13730293. A live audio webcast can be accessed by visiting the Investors & Media – News & Events section of atarabio.com. An archived replay will be available on the Company's website for 30 days following the live webcast.

 

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell

 

 

(CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco, California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.

 

Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the Company’s updated corporate strategy to focus as a leaner, R&D-centered organization, including (i) the staff reduction; and (ii) seeking a commercial partner for tab-cel in the U.S; (2) the potential benefits, safety and efficacy of tab-cel®; the timing and progress of tab-cel®, including (i) data and analyses from ALLELE study; (ii) tab-cel® clinical trials, and the occurrence, timing and outcome of Atara’s interactions and discussions with the FDA regarding a BLA submission for tab-cel®, (iii) the timing and outcome of the MAA for tab-cel®, (iv) the potential timing of the initiation or submission of the BLA for tab-cel®, and (iv) the timing of the EMA’s review of the MAA for tab-cel®; (3) the potential benefits, safety and efficacy of ATA188; the timing and progress of ATA188, including (i) regulatory designations for ATA188 granted by FDA and the impact thereof; (ii) data and analyses from ATA188 OLE study; (iii) ATA188 clinical trials, (iv) data and analyses from the planned interim analysis for the EMBOLD study, potential next steps for the program and planned discussions with FDA; and (v) Atara’s ability to successfully advance the development of ATA188; (4) the timing and progress of its CAR T programs, and the safety and efficacy of product candidates emerging from such programs, including (i) ATA2271 clinical trial, (ii) ATA3271 and ATA3219 preclinical development, (iii) termination of the strategic collaboration with Bayer for ATA2271 and ATA3271, and (iv) Atara’s ability to successfully advance the development of its CAR T programs; (5) Atara’s research and development activities; (6) Atara’s ability to reach critical value-generating milestones for its key pipeline assets or to generate value from such assets; and (7) Atara’s ability to advance development of its other programs. Because such statements deal with future events and are based on Atara’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the ongoing COVID-19 pandemic and the war in Ukraine, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Atara’s cash resources and need for additional capital; and other risks and uncertainties affecting Atara’s and its development programs, including those discussed in Atara’s filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

 

 

 

 

Financials

 

Atara Biotherapeutics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)

 

 

June 30,

 

 

December 31,

 

 

 

2022

 

 

2021

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

70,688

 

 

$

106,084

 

Short-term investments

 

 

260,623

 

 

 

264,984

 

Restricted cash

 

 

1,346

 

 

 

194

 

Accounts receivable

 

 

637

 

 

 

986

 

Prepaid expenses and other current assets

 

 

13,690

 

 

 

12,373

 

Total current assets

 

 

346,984

 

 

 

384,621

 

Property and equipment, net

 

 

8,328

 

 

 

53,780

 

Operating lease assets

 

 

73,582

 

 

 

26,159

 

Restricted cash - long-term

 

 

—

 

 

 

1,200

 

Other assets

 

 

7,227

 

 

 

2,367

 

Total assets

 

$

436,121

 

 

$

468,127

 

 

 

 

 

 

 

 

 

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

12,799

 

 

$

17,368

 

Accrued compensation

 

 

16,317

 

 

 

25,150

 

Accrued research and development expenses

 

 

15,125

 

 

 

13,451

 

Deferred revenue

 

 

1,671

 

 

 

40,760

 

Other current liabilities

 

 

19,776

 

 

 

9,057

 

Total current liabilities

 

 

65,688

 

 

 

105,786

 

Deferred revenue - long-term

 

 

43,329

 

 

 

55,708

 

Operating lease liabilities - long-term

 

 

63,999

 

 

 

25,518

 

Other long-term liabilities

 

 

5,626

 

 

 

1,501

 

Total liabilities

 

 $

178,642

 

 

$

188,513

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock—$0.0001 par value, 500,000 shares authorized as of June 30,2022 and December 31, 2021; 94,356 and 91,671 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively

 

 

9

 

 

 

9

 

Additional paid-in capital

 

 

1,794,449

 

 

 

1,744,695

 

Accumulated other comprehensive (loss) income

 

 

(2,618

)

 

 

(368

)

Accumulated deficit

 

 

(1,534,361

)

 

 

(1,464,722

)

Total stockholders’ equity

 

 

257,479

 

 

 

279,614

 

Total liabilities and stockholders’ equity

 

$

436,121

 

 

$

468,127

 

 

 

 

 

 

Atara Biotherapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

(In thousands, except per share amounts)

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

License and collaboration revenue

 

$

51,579

 

 

$

3,870

 

 

$

58,893

 

 

$

7,422

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

64,898

 

 

 

68,475

 

 

 

139,861

 

 

 

132,534

 

General and administrative

 

 

18,813

 

 

 

19,397

 

 

 

39,384

 

 

 

37,135

 

Total operating expenses

 

 

83,711

 

 

 

87,872

 

 

 

179,245

 

 

 

169,669

 

Loss from operations

 

 

(32,132

)

 

 

(84,002

)

 

 

(120,352

)

 

 

(162,247

)

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain on sale of ATOM Facility

 

 

50,237

 

 

 

—

 

 

 

50,237

 

 

 

—

 

Interest and other income, net

 

 

361

 

 

 

225

 

 

 

476

 

 

 

135

 

Total other (expense), net

 

 

50,598

 

 

 

225

 

 

 

50,713

 

 

 

135

 

Income (loss) before provision for income taxes

 

 

18,466

 

 

 

(83,777

)

 

 

(69,639

)

 

 

(162,112

)

Provision for income taxes

 

 

—

 

 

 

16

 

 

 

—

 

 

 

16

 

Net income (loss)

 

$

18,466

 

 

$

(83,793

)

 

$

(69,639

)

 

$

(162,128

)

Other comprehensive gain (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale securities

 

 

(726

)

 

 

(99

)

 

 

(2,250

)

 

 

(234

)

Comprehensive income (loss)

 

$

17,740

 

 

$

(83,892

)

 

$

(71,889

)

 

$

(162,362

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net earnings (loss) per common share

 

$

0.18

 

 

$

(0.91

)

 

$

(0.69

)

 

$

(1.77

)

Diluted net earnings (loss) per common share

 

$

0.18

 

 

$

(0.91

)

 

$

(0.69

)

 

$

(1.77

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average basic shares outstanding

 

 

101,601

 

 

 

92,152

 

 

 

101,166

 

 

 

91,806

 

Weighted-average diluted shares outstanding

 

 

101,866

 

 

 

92,152

 

 

 

101,166

 

 

 

91,806

 

 

 

 

INVESTORS & MEDIA:

Investors

Eric Hyllengren

805-395-9669

ehyllengren@atarabio.com

 

Media

Alex Chapman

805-456-4772

achapman@atarabio.com

 

 

 

 

 

 

 EX-101.PRE 3 atra-20220802_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 atra-20220802_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.SCH 5 atra-20220802.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document And Entity Information
Aug. 02, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 02, 2022
Entity Registrant Name Atara Biotherapeutics, Inc.
Entity Central Index Key 0001604464
Entity Emerging Growth Company false
Entity File Number 001-36548
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-0920988
Entity Address, Address Line One 611 Gateway Boulevard
Entity Address, Address Line Two Suite 900
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 278-8930
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ATRA
Security Exchange Name NASDAQ
XML 7 atra-20220802_htm.xml IDEA: XBRL DOCUMENT 0001604464 2022-08-02 2022-08-02 0001604464 false 8-K 2022-08-02 Atara Biotherapeutics, Inc. DE 001-36548 46-0920988 611 Gateway Boulevard Suite 900 South San Francisco CA 94080 (650) 278-8930 false false false false Common Stock, par value $0.0001 per share ATRA NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports atra-20220802.htm atra-20220802.xsd atra-20220802_lab.xml atra-20220802_pre.xml atra-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "atra-20220802.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "atra-20220802.htm" ] }, "labelLink": { "local": [ "atra-20220802_lab.xml" ] }, "presentationLink": { "local": [ "atra-20220802_pre.xml" ] }, "schema": { "local": [ "atra-20220802.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "atra", "nsuri": "http://www.atarabio.com/20220802", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "atra-20220802.htm", "contextRef": "C_39d9c968-b983-437a-ae17-1d2997b4fca9", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "atra-20220802.htm", "contextRef": "C_39d9c968-b983-437a-ae17-1d2997b4fca9", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.atarabio.com/20220802/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0000950170-22-015519-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-015519-xbrl.zip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end